Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin Link To Pancreatic Cancer Risk In Study “Inconclusive” – Bayer

This article was originally published in The Tan Sheet

Executive Summary

Results of a newly published study indicating that women who use aspirin two or more times per week are at an increased risk of pancreatic cancer are not "conclusive," Bayer Consumer Care maintains

You may also be interested in...



Women, aspirin & cancer

"Extended aspirin use may be associated with significantly increased cancer risk among women," Eva Schernhammer, MD, Harvard University Medical School, et al., reported at a meeting of the American Association for Cancer Research in Phoenix Oct. 26-30. Among 88,378 participants in the Nurses' Health Study, researchers identified 161 cases of pancreatic cancer in previously cancer-free individuals. The risk increased 58% for women who took aspirin twice a week or more for more than 20 years. "These findings, if confirmed, add another variable to the complex risk-benefit profile of aspirin," Schernhammer cautioned...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS096333

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel